Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease...
18 KB (1,638 words) - 20:03, 20 December 2023
a combination of torcetrapib and atorvastatin, an increase in cardiovascular events and mortality. A compound related to torcetrapib, Dalcetrapib (investigative...
14 KB (1,736 words) - 21:23, 17 May 2024
in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib). Failed: Torcetrapib: failed in...
9 KB (790 words) - 14:01, 11 July 2024
Pfizer's CETPi drug (torcetrapib) failed in the final stages of clinical development. Pfizer terminated the development program for torcetrapib and reportedly...
6 KB (569 words) - 12:24, 18 May 2024
increasing HDL by any means is not necessarily helpful. For example, the drug torcetrapib is the most effective agent currently known for raising HDL (by up to...
100 KB (11,155 words) - 18:45, 24 August 2024
replacing Henry McKinnell. On December 3, 2006, Pfizer ceased development of torcetrapib, a drug that increases production of HDL, which reduces LDL thought to...
167 KB (14,521 words) - 12:08, 29 August 2024
previous acute coronary events. Other CETP inhibitors:[citation needed] Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases...
4 KB (227 words) - 06:29, 16 June 2024
Cholesteryl ester transfer protein (CETP) inhibitors include the agents torcetrapib, anacetrapib and obicetrapib. They block transfer of cholesterol from...
30 KB (2,961 words) - 13:47, 30 May 2024
modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone...
8 KB (707 words) - 13:26, 11 July 2024
cardiovascular risk score for early detection of the harmful effects of Torcetrapib. In 2016 they also developed a test to diagnose latent tuberculosis,...
14 KB (1,312 words) - 06:58, 13 February 2024